Neuro-Oncology

Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions.  25:4-25. 2023

EGFR, the Lazarus target for precision oncology in glioblastoma.  24:2035-2062. 2022

Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma.  24:1964-1975. 2022

Targeting adaptive radioresistance in glioblastoma.  24:1071-1073. 2022

Multimodal platform for assessing drug distribution and response in clinical trials.  24:64-77. 2022

Potential role of carbon ion radiotherapy in chromothripsis-induced medulloblastoma and other malignancies.  23:1991-1992. 2021

IMMU-09. HUMAN MICROBIOTA INFLUENCE THE EFFICACY OF IMMUNOTHERAPY IN A MOUSE MODEL OF GLIOBLASTOMA.  23:vi93-vi94. 2021

NFB-09. ENROLLMENT AND CLINICAL CHARACTERISTICS OF NEWLY DIAGNOSED, NEUROFIBROMATOSIS TYPE 1 ASSOCIATED OPTIC PATHWAY GLIOMA (NF1-OPG): PRELIMINARY RESULTS FROM AN INTERNATIONAL MULTI-CENTER NATURAL HISTORY STUDY.  22:iii419-iii419. 2020

Mapping uncharted territory: A gene expression signature for precision glioblastoma therapeutics.  22:1713-1714. 2020

CTNI-10. MAINTENANCE CHEMOTHERAPY USING BEVACIZUMAB FOR NEUROFIBROMATOSIS 2 PATIENTS WITH HEARING LOSS AND PROGRESSIVE VESTIBULAR SCHWANNOMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY (NF104).  22:ii43-ii43. 2020

TMOD-19. INDIVIDUAL SPECIFIC HUMAN GUT MICROBE COMMUNITIES INFLUENCE RESPONSE TO IMMUNOTHERAPY IN A HUMANIZED MICROBIOME MOUSE MODEL OF GLIOMA.  22:ii232-ii232. 2020

CTNI-10. MAINTENANCE CHEMOTHERAPY USING BEVACIZUMAB FOR NEUROFIBROMATOSIS 2 PATIENTS WITH HEARING LOSS AND PROGRESSIVE VESTIBULAR SCHWANNOMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY (NF104).  22:ii43-ii43. 2020

A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: A Neurofibromatosis Clinical Trials Consortium study.  22:1527-1535. 2020

Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: Conclusions from the Adult Brain Tumor Consortium's first workshop on CNS drug delivery.  22:1422-1424. 2020

Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival.  22:1359-1367. 2020

A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE).  22:705-717. 2020

A troublesome burden, the amplification of EGFR in glioblastoma!.  22:594-595. 2020

Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients.  22:601-612. 2020

ICOSLG-mediated regulatory T-cell expansion and IL-10 production promote progression of glioblastoma.  22:333-344. 2020

The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients.  21:1498-1508. 2019

ATIM-32. PREDICTORS OF IMPROVED SURVIVAL FOLLOWING ONCOLYTIC VIRUS TREATMENT IN PATIENTS WITH RECURRENT GLIOBLASTOMA: GENE EXPRESSION ANALYSIS FROM THE PHASE IB G207 CLINICAL TRIAL.  21:vi8-vi8. 2019

TMOD-19. ELUCIDATING THE RESISTANCE TO IMMUNOTHERAPY IN BRAIN TUMORS USING A HUMANIZED MICROBIOME MOUSE MODEL.  21:vi266-vi266. 2019

ATIM-32. PREDICTORS OF IMPROVED SURVIVAL FOLLOWING ONCOLYTIC VIRUS TREATMENT IN PATIENTS WITH RECURRENT GLIOBLASTOMA: GENE EXPRESSION ANALYSIS FROM THE PHASE IB G207 CLINICAL TRIAL.  21:vi8-vi8. 2019

A multi-institutional analysis of presentation and outcomes for leptomeningeal disease recurrence after surgical resection and radiosurgery for brain metastases.  21:1049-1059. 2019

Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus..  21:837-853. 2019

Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR -amplified, recurrent glioblastoma: Results from an international phase I multicenter trial.  21:106-114. 2019

TMOD-27. HUMANIZED MICROBIOME MOUSE MODELS TO ENHANCE IMMUNOTHERAPY IN GLIOBLASTOMA.  20:vi274-vi274. 2018

Reactive species balance via GTP cyclohydrolase i regulates glioblastoma growth and tumor initiating cell maintenance.  20:1055-1067. 2018

NFM-01. NF105: A PHASE II PROSPECTIVE STUDY OF CABOZANTINIB (XL184) FOR PLEXIFORM NEUROFIBROMAS IN SUBJECTS WITH NEUROFIBROMATOSIS TYPE 1: A NEUROFIBROMATOSIS CLINICAL TRIAL CONSORTIUM (NFCTC) STUDY.  20:i142-i142. 2018

NFM-06. NF106: PHASE 2 TRIAL OF THE MEK INHIBITOR PD-0325901 IN ADOLESCENTS AND ADULTS WITH NF1-RELATED PLEXIFORM NEUROFIBROMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY.  20:i143-i143. 2018

NFM-09. PRELIMINARY REPORT OF A MULTICENTER, PHASE 2 STUDY OF BEVACIZUMAB IN CHILDREN AND ADULTS WITH NEUROFIBROMATOSIS 2 AND PROGRESSIVE VESTIBULAR SCHWANNOMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY.  20:i144-i144. 2018

Glioma through the looking GLASS: Molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium.  20:873-884. 2018

Hospice care, cancer-directed therapy, and Medicare expenditures among older patients dying with malignant brain tumors.  20:986-993. 2018

NFM-01. NF105: A PHASE II PROSPECTIVE STUDY OF CABOZANTINIB (XL184) FOR PLEXIFORM NEUROFIBROMAS IN SUBJECTS WITH NEUROFIBROMATOSIS TYPE 1: A NEUROFIBROMATOSIS CLINICAL TRIAL CONSORTIUM (NFCTC) STUDY.  20:i142-i142. 2018

NFM-06. NF106: PHASE 2 TRIAL OF THE MEK INHIBITOR PD-0325901 IN ADOLESCENTS AND ADULTS WITH NF1-RELATED PLEXIFORM NEUROFIBROMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY.  20:i143-i143. 2018

NFM-09. PRELIMINARY REPORT OF A MULTICENTER, PHASE 2 STUDY OF BEVACIZUMAB IN CHILDREN AND ADULTS WITH NEUROFIBROMATOSIS 2 AND PROGRESSIVE VESTIBULAR SCHWANNOMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY.  20:i144-i144. 2018

A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: Results of NRG Oncology RTOG 0913.  20:666-673. 2018

Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02..  20:546-556. 2018

Longitudinal assessment of late-onset neurologic conditions in survivors of childhood central nervous system tumors: a Childhood Cancer Survivor Study report..  20:132-142. 2018

MerTK as a therapeutic target in glioblastoma.  20:92-102. 2018

Putting "multiforme" back into glioblastoma: Intratumoral transcriptome heterogeneity is a consequence of its complex morphology.  19:1570-1571. 2017

EXTH-30. THERAPEUTIC BENEFIT OF A KETOGENIC DIET THROUGH ALTERED GUT MICROBIOTA IN A MOUSE MODEL OF GLIOMA.  19:vi78-vi78. 2017

RARE-19. MULTICENTER, PHASE 2 STUDY OF BEVACIZUMAB IN CHILDREN AND ADULTS WITH NEUROFIBROMATOSIS 2 AND PROGRESSIVE VESTIBULAR SCHWANNOMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY.  19:vi215-vi215. 2017

TMIC-07. HIGH ALDEHYDE DEHYDROGENASE ACTIVITY IDENTIFIES BRAIN METASTASIS-INITIATING CELLS IN BREAST CANCER.  19:vi244-vi244. 2017

TMIC-31. MLK4 IS REQUIRED FOR METASTASIS INITIATION IN THE BRAIN.  19:vi250-vi250. 2017

TMIC-36. CROSSTALK OF GLIOMA STEM CELLS WITH VASCULAR ENDOTHELIAL CELLS PERSISTS THEIR PRONEURAL PHENOTYPE AND THERAPY RESISTANCE VIA ENDOCAN-CD11A INTERACTION.  19:vi251-vi251. 2017

Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.  19:1469-1480. 2017

Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.  19:1481-1493. 2017

RARE-19. MULTICENTER, PHASE 2 STUDY OF BEVACIZUMAB IN CHILDREN AND ADULTS WITH NEUROFIBROMATOSIS 2 AND PROGRESSIVE VESTIBULAR SCHWANNOMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY.  19:vi215-vi215. 2017

Genomic profiles of low-grade murine gliomas evolve during progression to glioblastoma.  19:1237-1247. 2017

When less is better: Care of the elderly with glioblastoma.  19:879. 2017

Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas.  19:845-852. 2017

Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813..  19:252-258. 2017

Reactive astrocytes potentiate tumor aggressiveness in a murine glioma resection and recurrence model.  18:1622-1633. 2016

RBIO-05. miRNAs THAT CONFER GLIOBLASTOMA RESISTANCE: IS THE COMBINATION MERELY A SUM OF THE PARTS?.  18:vi173-vi173. 2016

TMOD-18. THREE-DIMENSIONAL MICROTUMORS IN PHYSIOLOGIC MICROENVIRONMENTS MAINTAIN BRAIN TUMOR INITIATING CELLS.  18:vi210-vi210. 2016

Creation of an NCI comparative brain tumor consortium: Informing the translation of new knowledge from canine to human brain tumor patients.  18:1209-1218. 2016

Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide.  18:962-973. 2016

Homeobox C9 suppresses Beclin1-mediated autophagy in glioblastoma by directly inhibiting the transcription of death-associated protein kinase 1.  18:819-829. 2016

Isorhapontigenin suppresses growth of patient-derived glioblastoma spheres through regulating miR-145/SOX2/cyclin D1 axis..  18:830-839. 2016

MB-41INTRAVENTRICULAR ONCOLYTIC ENGINEERED HERPES SIMPLEX VIRUS PROLONGS SURVIVAL AND REDUCES SPINAL METASTASES IN MICE BEARING HUMAN GROUP 3 MEDULLOBLASTOMA.  18:iii106.1-iiiii106. 2016

PCM-07COMPARATIVE GENOMICS: THE DOG AS A TRANSLATIONAL MODEL FOR MENINGIOMA.  18:iii140-iii140. 2016

Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses.  18:227-235. 2016

ATCT-04RETROSPECTIVE ANALYSIS OF TUMOR TREATING FIELDS (TTFIELDS) IN ADULTS WITH GLIOBLASTOMA: SAFETY PROFILE OF THE OPTUNE™ MEDICAL DEVICE IN PATIENTS WITH IMPLANTED NON-PROGRAMMABLE SHUNTS, PROGRAMMABLE SHUNTS, AND PACEMAKERS/DEFIBRILLATORS.  17:v1-v1. 2015

TMIC-17LOSS OF SOCS3 IN MYELOID CELLS PROMOTES A DECREASED M2 MACROPHAGE PHENOTYPE AND AN INCREASED CYTOTOXIC T-CELL RESPONSE IN A SYNGENEIC MODEL OF GLIOMA.  17:v218-v218. 2015

Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma.  17:1275-1283. 2015

Ras-mediated modulation of pyruvate dehydrogenase activity regulates mitochondrial reserve capacity and contributes to glioblastoma tumorigenesis.  17:1220-1230. 2015

Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: Results of the open-label, controlled, randomized phase II CORE study.  17:708-717. 2015

Connexin 30 expression inhibits growth of human malignant gliomas but protects them against radiation therapy.  17:392-406. 2015

Development of a Sox2 reporter system modeling cellular heterogeneity in glioma.  17:361-371. 2015

Contemporary murine models in preclinical astrocytoma drug development.  17:12-28. 2015

Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.  17:430-439. 2015

BM-13THE (F)UTILITY OF PREDICTIVE MODELS.  16:v34-v35. 2014

ME-13LOSS OF SOCS3 IN MYELOID CELLS DELAYS TUMOR GROWTH AND PROLONGS SURVIVAL IN A SYNGENEIC MODEL OF GLIOBLASTOMA.  16:v122-v122. 2014

Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors.  16:1541-1546. 2014

Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: A neurofibromatosis clinical trials consortium phase II study.  17:596-603. 2014

Integrated analysis identifies different metabolic signatures for tumor-initiating cells in a murine glioblastoma model.  16:1048-1056. 2014

Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.  16:707-718. 2014

Where are we now? and where are we going? A report from the Accelerate Brain Cancer Cure (ABC²) Low-grade Glioma Research Workshop.  16:173-178. 2014

Cooperativity between MAPK and PI3K signaling activation is required for glioblastoma pathogenesis.  15:1317-1329. 2013

NABTT 0502: A phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.  15:490-496. 2013

CD38 deficiency in the tumor microenvironment attenuates glioma progression and modulates features of tumor-associated microglia/macrophages.  14:1037-1049. 2012

Initial treatment patterns over time for anaplastic oligodendroglial tumors.  14:761-767. 2012

Response to Weltman and Fleury Malheiros, re Lassman et al..  14:677-678. 2012

Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma.  13:1324-1330. 2011

Proteomics of gliomas: Initial biomarker discovery and evolution of technology.  13:926-942. 2011

Gene-protein correlation in single cells.  13:880-885. 2011

International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors.  13:649-659. 2011

Glycogen synthase kinase 3β inhibition enhances repair of DNA double-strand breaks in irradiated hippocampal neurons.  13:459-470. 2011

Tamoxifen inhibits malignant peripheral nerve sheath tumor growth in an estrogen receptor-independent manner.  13:28-41. 2011

Analysis of specialized DNA polymerases expression in human gliomas: Association with prognostic significance.  12:679-686. 2010

INTERLEUKIN-17A PROMOTES AUTOIMMUNITY BY SYNERGIZING WITH INTERLEUKIN-6 VIA A POSITIVE- FEEDBACK LOOP OF INTERLEUKIN-6 INDUCTION IN PRIMARY ASTROCYTES.  11:566-566. 2009

Characterization and immunotherapeutic potential of γδ T-cells in patients with glioblastoma.  11:357-367. 2009

Phase i and pharmacokinetic study of karenitecin in patients with recurrent malignant gliomas.  10:608-616. 2008

A pilot study: ¹³¹I-Antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.  10:182-189. 2008

Gene delivery into malignant glioma by infectivity-enhanced adenovirus: In vivo versus in vitro models.  9:280-290. 2007

High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: Long-term follow-up.  8:183-188. 2006

Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model.  7:213-224. 2005

Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis.  7:134-153. 2005

The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis.  7:122-133. 2005

Refining the staging evaluation of pineal regoin germinoma using neuroendoscopy and the presence of preoperative diabetes insipidus.  6:127-133. 2004

Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: Final report of NABTT 97-11.  6:21-27. 2004

Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11..  6:21-27. 2004

Myeloablative chemotherapy for recurrent aggressive oligodendroglioma.  2:114-119. 2000

Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression.  1:124-137. 1999